NIT’s lead product is Hyleukin-7, an engineered T cell amplifier designed to reconstitute and enhance antitumoral T cell immunity. Hyleukin-7 consists of homodimeric Interleukin-7 (IL-7) molecules, which are homeostatic cytokines that enhance the number and function of T cells, biologically fused to IgD/IgG4 immunoglobulin domain (hyFc®) as a safe and effective long-acting carrier.
NIT is currently conducting multiple clinical trials of Hyleukin-7, aiming at developing it as not only a first-in-class treatment of lymphopenia as a monotherapy, but also a breakthrough “enabling” drug to enhance cancer immunotherapeutics, which may substantially enhance the anti-tumor efficacy of the conventional cancer treatments and/or novel immunotherapies harnessing T cell immunity as a combination therapy.
Based in Rockville, Maryland, NIT has the core competency of global clinical development and business development actively networking with many global leading research and development organizations. Founded in 2014, NIT was spun off from Genexine, a leading Korean biotech company listed in KOSDAQ.